What are Antiplatelet agent drugs?

Antiplatelet agent drugs are pharmacologic agents that share a common mechanism (typically targeting Cyclooxygenase-1 (COX-1)). 6 are currently marketed, with 4 more in clinical development.

What are the marketed Antiplatelet agent drugs?

Marketed Antiplatelet agent drugs include Single antiplatelet therapy, Traditional Antiplatelet Therapy Control Group, Antiplatelet Agents, Antiplatelet therapy, PL-ASA, aspirin and/or clopidogrel.

Antiplatelet agent

6 marketed 4 in Phase 3

This page covers all Antiplatelet agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Cyclooxygenase-1 (COX-1), COX (aspirin); P2Y12 receptor (clopidogrel).

Targets

Cyclooxygenase-1 (COX-1) · COX (aspirin); P2Y12 receptor (clopidogrel)

Marketed (6)

Single antiplatelet therapy · China National Center for Cardiovascular Diseases · Cardiovascular
Single antiplatelet therapy inhibits platelet aggregation to reduce thrombotic events in cardiovascular disease.
Traditional Antiplatelet Therapy Control Group · Sichuan Provincial People's Hospital · Cardiovascular
Traditional antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events.
Antiplatelet Agents · Beijing Tiantan Hospital · Cardiovascular
Antiplatelet agents inhibit platelet aggregation and clot formation by blocking platelet activation pathways.
Antiplatelet therapy · Assistance Publique - Hôpitaux de Paris · Cardiovascular
Antiplatelet therapy inhibits platelet aggregation to prevent blood clot formation and reduce thrombotic events.
PL-ASA · PLx Pharma · Cardiovascular
PL-ASA is a combination formulation of aspirin with a protective coating designed to reduce gastrointestinal irritation and bleeding risk while maintaining antiplatelet efficacy.
aspirin and/or clopidogrel · Asan Medical Center · Cardiovascular
Aspirin and clopidogrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent blood clots.

Phase 3 pipeline (4)

Start antiplatelet monotherapy · The George Institute for Global Health, China · Cardiovascular
Antiplatelet monotherapy reduces blood clot formation by inhibiting platelet aggregation through a single antiplatelet agent.
Antiplatelet therapy (AP) · Centre Hospitalier Universitaire de Saint Etienne · Cardiovascular
Antiplatelet therapy inhibits platelet aggregation to prevent thrombotic events by blocking platelet activation pathways.
Antiplatelet Monotherapy · Hospital Israelita Albert Einstein · Cardiovascular
Antiplatelet monotherapy inhibits platelet aggregation to reduce thrombotic events.
Antiplatelet-only strategy · Icahn School of Medicine at Mount Sinai · Cardiovascular
An antiplatelet-only strategy inhibits platelet aggregation to prevent thrombotic events without additional anticoagulation.